-
CD160 and CD200 are expressed in B cells in chronic lymphocytic leukemia and are absent in other mature B-cell neoplasms.
-
Data suggest that CD160 may become a useful marker in the clinical diagnosis and prognosis of chronic lymphocytic leukemia.
-
elevated CD160 expression on natural killer (NK) cells plays an important role in NK cell loss in atherosclerosis.
-
CD160-expressing human NK cells are costimulated by HVEM expressed in the environment to enhance cytolytic function and cytokine production.
-
analysis of how NK1 receptor Gs versus Gq proteins and beta-arrestin signaling is determined by interactions in the water hydrogen bond network
-
identified 13 ADCC-activated genes. Six gene expression assays including 8 of the 13 genes (CCL3, CCL4/CCL4L1/CCL4L2, CD160, IFNG, NR4A3 and XCL1/XCL2) were analyzed in 127 kidney biopsies
-
CD160FCA offers a simple assay for minimal residual disease detection in CLL and gives prognostic information across different CLL risk groups.
-
report high frequencies of CD160 on CD8+ T cells, with significantly higher levels on HTLV-1 specific CD8+ T cells
-
A population of CD4+ CD160+ T lymphocytes was identified in circulating cutaneous T cells.
-
Antibodies targeting CD160-GPI complement the blockade of PD-1 to enhance HIV-specific T-cell responses and warrant further investigation in the development of novel immunotherapeutic approaches.
-
CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.
-
results indicate that CD160+ lymphocytes could be able to play a role in the maintenance of healthy pregnancy
-
circulating NK cells from PNH patients exhibit a self-MHC class I molecule reactive effector function, which could be mediated through the recruitment of CD160-TM receptor.
-
The results of a mutagenesis study of HVEM suggest that the CD160 binding region on HVEM was slightly different from, but overlapped with, the BTLA binding site.
-
demonstrated CD160 expression in 98% of chronic lymphocytic leukemia cases, 100% of hairy cell leukemia cases, 15% of mantle cell lymphoma in the leukemic phase, and 16% of other B-cell lymphoproliferative disorders
-
A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.
-
soluble CD160, produced by mast cells, may have a role in T-cell-mast cell interactions in vivo
-
Activation through CD160 leads to PI3K-dependent chronic lymphocytic leukemia protection from spontaneous in vitro apoptosis, as well as cellular activation with cell cycle progression and cytokine production.
-
BY55 functions as a co-receptor in TCR signal transduction of a human cytotoxic effector T lymphocyte subset lacking CD28 expression
-
CD94-expressing cells with cytolytic activity against the recipient's leukemic and tumor cells without enhancement of alloresponse might be able to be expanded from donor G-PBMCs.
